Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 16/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 15/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.66 |
| ▸ | HTR1A | P08908 | 3/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL911790 | 0.93 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL911791 | 0.93 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL911331 | 0.81 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL911512 | 0.81 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL911332 | 0.81 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL5453058 | 0.79 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL14410831 | 0.79 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL5453061 | 0.79 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL29966 | 0.79 | SLC6A2 (0.61) | SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL12093264 | 0.79 | SLC6A2 (0.49) | SLC6A4SLC6A2SLC6A3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933229-B2 | 8-azabicyclo[3.2.1]octane-8-carboxamide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-8933229-B2 | 8-azabicyclo[3.2.1]octane-8-carboxamide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| WO-2011059021-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | HDAC10, HDAC11, HDAC1 | SLC6A4 3419/4885SLC6A2 2458/4885SLC6A3 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.